Henry I. Miller

Robert Wesson Fellow in Scientific Philosophy and Public Policy

Henry I. Miller, MS, MD, is the Robert Wesson Fellow in Scientific Philosophy and Public Policy at the Hoover Institution. His research focuses on public policy toward science and technology, encompassing a number of areas, including pharmaceutical development, genetic engineering in agriculture, models for regulatory reform, and the emergence of new viral diseases.

Miller served for fifteen years at the US Food and Drug Administration (FDA) in a number of posts. He was the medical reviewer for the first genetically engineered drugs to be evaluated by the FDA and thus instrumental in the rapid licensing of human insulin and human growth hormone. Thereafter, he was a special assistant to the FDA commissioner and the founding director of the FDA's Office of Biotechnology. During his government service, Miller participated frequently on various expert and policy panels as a representative of the FDA or the US government. As a government official, Miller received numerous awards and citations.

Since coming to the Hoover Institution, Miller has become well known not only for his contributions to scholarly journals but also for his articles and books that make science, medicine, and technology accessible. His work has been widely published in many languages. Monographs include Policy Controversy in Biotechnology: An Insider's View; To America's Health: A Model for Reform of the Food and Drug Administration; and The Frankenfood Myth: How Protest and Politics Threaten the Biotech Revolution. Barron's selected The Frankenfood Myth as one of the 25 Best Books of 2004. In addition, Miller has published extensively in a wide spectrum of scholarly journals and popular publications worldwide, including The Lancet, Journal of the American Medical Association, Science, the Nature family of journals, Chronicle of Higher Education, Forbes, National Review, Wall Street Journal, New York Times, the Guardian, Defining Ideas, and the Financial Times. He is a regulator contributor to Forbes.com and frequently appears on the nationally syndicated radio programs of John Batchelor and Lars Larson.

Miller was selected by the editors of Nature Biotechnology as one of the people who had made the "most significant contributions" to biotechnology during the previous decade. He serves on numerous editorial boards.

Filter By:



Recent Commentary

Analysis and Commentary

EPA's Bungling And Judicial Overreach Squeeze The Citrus Industry

by Henry I. Millervia Forbes
Wednesday, October 7, 2015

U.S. citrus farmers are feeling squeezed by a recent decision of the ultra-liberal San Francisco-based U.S. Court of Appeals for the Ninth Circuit. A three-judge panel of the court in September vacated, or invalidated, the EPA’s approval of sulfoxaflor, a highly effective new insecticide used widely on citrus.


Biotech Regulation: Will Government Become The Solution Instead Of The Problem?

by Henry I. Miller, John Cohrssenvia Forbes
Wednesday, September 30, 2015

The advent of molecular genetic engineering techniques in the 1970’s promised potential breakthroughs in a wide range of consumer products–more efficient means for producing pharmaceuticals, improved food plants, safer “biorational” pesticides, cleaner energy from biomass and improved traits for animals.

Analysis and Commentary

GMOs And Junk Science

by Henry I. Miller, Kavin Senapathyvia Project Syndicate
Thursday, September 24, 2015

In today’s media landscape, where unfounded opinions, hype, and rumors are rife, the scientific method – the means by which we determine, based on empirical and measurable evidence, what is true – should serve as a touchstone of reality.

Blank Section (Placeholder)Featured

The Dirty Truth About "Organic"

by Henry I. Millervia Defining Ideas
Wednesday, September 23, 2015

Conventional foods are much cheaper, safer, and environmentally effective than their hyped up counterparts. 


Government Favors And Subsidies To Organic Agriculture: Follow The Money

by Henry I. Miller, Julie Kellyvia Forbes
Wednesday, September 23, 2015

As the media continue to burnish the “good health” halo of the organic industry, another new narrative is emerging–that “Big Ag” lobbyists are paying off lawmakers to advance their agenda while advocates of the poor, beleaguered organic industry are camped mournfully outside the Capitol in their compost-soiled overalls.


Will A New FDA Head Usher In A More Enlightened Era?

by Henry I. Millervia Forbes
Tuesday, September 22, 2015

President Obama has nominated a deputy commissioner of the Food and Drug Administration, Dr. Robert Califf, to head the agency.

Analysis and Commentary

What Politicians Should Learn about Vaccination

by Henry I. Millermentioning Kori Schakevia National Review
Saturday, September 19, 2015

My Hoover Institution colleague Kori Schake wrote about last Wednesday’s GOP debate that, when it comes to foreign policy, the contenders still have a lot to learn. The same is true about vaccines and vaccination policy.


Supreme Court Free-Speech Decision Clobbers GMO Food-Labeling Activists

by Henry I. Miller, John Cohrssen, Drew L. Kershenvia Forbes
Wednesday, September 16, 2015

Controversy continues to rage over whether foods from genetically engineered plants should have to be labeled as such. The battle has been fought in the media, in state legislatures, through referendum issues and in federal courts. Most mandatory-labeling proposals have failed, and none is in effect.


A New, Bizarre Activist Scam: Formaldehyde In GMO Soybeans

by Henry I. Miller, Kavin Senapathyvia Forbes
Wednesday, September 9, 2015

Science encompasses a vast body of knowledge—the boring stuff we memorize in tenth-grade chemistry class, for example–but more important, it defines the methods by which this body of information continuously grows and is refined and organized.

Analysis and Commentary

Feds’ Policy Blunders Allow Legionnaire’s Disease Outbreaks

by Henry I. Millervia Daily Caller (DC)
Tuesday, September 1, 2015

During the past two weeks, a couple dozen residents of the Quincy Veterans home in Illinois have contracted Legionnaire’s disease and four have died. During this same period, six inmates at California’s San Quentin prison have been diagnosed with the infection, and several dozen more with suggestive symptoms are under observation.